AR123187A1 - Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer - Google Patents
Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- AR123187A1 AR123187A1 ARP210102218A ARP210102218A AR123187A1 AR 123187 A1 AR123187 A1 AR 123187A1 AR P210102218 A ARP210102218 A AR P210102218A AR P210102218 A ARP210102218 A AR P210102218A AR 123187 A1 AR123187 A1 AR 123187A1
- Authority
- AR
- Argentina
- Prior art keywords
- residues
- polypeptide
- immunotherapeutic composition
- seq
- nucleic acid
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un polipéptido que comprende un primer péptido que comprende 3 - 10 aminoácidos de los residuos 1 - 10 ó 12 - 25 de la SEQ ID Nº 01 en enlace con un segundo péptido que comprende 3 - 10 aminoácidos de los residuos 81 - 140 de la SEQ ID Nº 02. Reivindicación 22: Una composición inmunoterapéutica, que comprende el polipéptido de cualquiera de las reivindicaciones 1 a 21, donde el polipéptido está enlazado a un portador. Reivindicación 26: Una formulación farmacéutica que comprende (a) el polipéptido de cualquiera de las reivindicaciones 1 a 21 o la composición inmunoterapéutica de cualquiera de las reivindicaciones 22 a 25 y (b) al menos un adyuvante. Reivindicación 35: Una composición inmunoterapéutica, que comprende una primera secuencia de péptidos que comprende 3 - 10 residuos de aminoácidos de los primeros diez residuos del extremo N o los residuos 12 a 25 de la SEQ ID Nº 01 y una segunda secuencia de péptidos que comprende 3 - 8 aminoácidos de los residuos 81 - 140 de la SEQ ID Nº 02. Reivindicación 46: Una composición farmacéutica que comprende la composición inmunoterapéutica de cualquiera de las reivindicaciones 35 a 45 y al menos un adyuvante. Reivindicación 51: Un ácido nucleico que comprende una secuencia de ácido nucleico que codifica un polipéptido de cualquiera de las reivindicaciones 1 a 21 de la composición inmunoterapéutica de las reivindicaciones 35 a 39. Reivindicación 52: Una composición inmunoterapéutica de ácido nucleico que comprende el ácido nucleico de la reivindicación 51 y al menos un adyuvante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080619P | 2020-09-18 | 2020-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123187A1 true AR123187A1 (es) | 2022-11-09 |
Family
ID=80777125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102218A AR123187A1 (es) | 2020-09-18 | 2021-08-09 | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230355729A1 (es) |
| EP (1) | EP4213941A4 (es) |
| JP (1) | JP2023541670A (es) |
| KR (1) | KR20230087499A (es) |
| CN (1) | CN116438191A (es) |
| AR (1) | AR123187A1 (es) |
| AU (1) | AU2021345483A1 (es) |
| CA (1) | CA3192387A1 (es) |
| IL (1) | IL301262A (es) |
| MX (1) | MX2023003008A (es) |
| TW (1) | TW202227464A (es) |
| WO (1) | WO2022060488A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| AU2023225283A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014031697A2 (en) * | 2012-08-21 | 2014-02-27 | The Institute Of Molecular Medicine | COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN |
| UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| CA2944402A1 (en) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| EP3277302A4 (en) * | 2015-04-01 | 2018-12-05 | The Scripps Research Institute | Methods and compositions related to gpcr agonist polypeptides |
| MX2022014453A (es) * | 2020-05-19 | 2023-02-09 | Othair Prothena Ltd | Vacuna multiepitopo para el tratamiento de la enfermedad de alzheimer. |
| KR20230080397A (ko) * | 2020-08-07 | 2023-06-07 | 오타이르 프로테나 리미티드 | 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신 |
-
2021
- 2021-08-06 WO PCT/US2021/045058 patent/WO2022060488A1/en active Application Filing
- 2021-08-06 CN CN202180064030.7A patent/CN116438191A/zh active Pending
- 2021-08-06 CA CA3192387A patent/CA3192387A1/en active Pending
- 2021-08-06 AU AU2021345483A patent/AU2021345483A1/en active Pending
- 2021-08-06 US US18/245,532 patent/US20230355729A1/en active Pending
- 2021-08-06 KR KR1020237012950A patent/KR20230087499A/ko active Search and Examination
- 2021-08-06 JP JP2023517698A patent/JP2023541670A/ja active Pending
- 2021-08-06 MX MX2023003008A patent/MX2023003008A/es unknown
- 2021-08-06 IL IL301262A patent/IL301262A/en unknown
- 2021-08-06 EP EP21869944.5A patent/EP4213941A4/en active Pending
- 2021-08-09 AR ARP210102218A patent/AR123187A1/es unknown
- 2021-08-09 TW TW110129344A patent/TW202227464A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021345483A1 (en) | 2023-04-13 |
| EP4213941A4 (en) | 2024-09-25 |
| IL301262A (en) | 2023-05-01 |
| MX2023003008A (es) | 2023-04-10 |
| CN116438191A (zh) | 2023-07-14 |
| US20230355729A1 (en) | 2023-11-09 |
| JP2023541670A (ja) | 2023-10-03 |
| EP4213941A1 (en) | 2023-07-26 |
| TW202227464A (zh) | 2022-07-16 |
| KR20230087499A (ko) | 2023-06-16 |
| WO2022060488A1 (en) | 2022-03-24 |
| CA3192387A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11998597B2 (en) | Vaccine against RSV | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| AR105616A1 (es) | Proteínas de fusión | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| DOP2021000197A (es) | Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea | |
| RU2010110564A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| PE20210376A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| RU2010110567A (ru) | Пептид foxm1 и включающее его медицинское средство | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| CO6190536A2 (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| JP2015505831A5 (es) | ||
| AR123189A1 (es) | VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| RU2009129531A (ru) | Вакцины на основе пептида foxp3 | |
| PE20230826A1 (es) | Peptidos y combinaciones de peptidos para uso en inmunoterapia contra la infeccion por sars-cov-2 | |
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие | |
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| AR112785A1 (es) | Composición de péptidos asociados a tumores proliferativos e inmunógeno anti-cáncer relacionado para el tratamiento de cánceres de pulmón y otros cánceres | |
| RU2019115303A (ru) | Вакцинные конструкты и их применения против инфекций стафилококка | |
| CL2023001796A1 (es) | Composiciones que comprenden ciclotidos y otros péptidos insecticidas y usos de las mismas | |
| RU2020101972A (ru) | Модифицированная l-аспарагиназа |